Assessing Type 2 Diabetes and GLP-1 agonist response trajectories with a proteogenomic atlas of disease progression
By integrating proteogenomic data from 42,000 UK Biobank participants with Mendelian randomization and semaglutide trial results, this study maps the distinct causal trajectories of adiposity, insulin resistance, and glycemia in Type 2 diabetes progression and identifies persistent protein dysregulations that drive residual cardiovascular risk despite GLP-1 agonist treatment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Type 2 diabetes is often described as a problem of sugar, but the body's struggle with the disease is far more complex than a single number on a blood test. The condition develops through a messy, overlapping series of biological shifts involving how the body stores fat, how it resists the hormone insulin, and how it manages blood sugar. For decades, doctors have tried to understand these shifts by looking at patients at a single moment in time, grouping them into categories like "normal," "pre-diabetic," or "diabetic." However, this approach often misses the unique biological pathways that drive the disease in different people. It is like trying to understand a storm by only looking at the sky at noon; you see the clouds, but you miss the wind patterns and pressure changes that caused them. To truly treat the disease and prevent its most dangerous complications, such as heart disease, scientists need a map that shows how the body's internal chemistry changes as the disease progresses and how it responds to treatment.
A team of researchers at Harvard Medical School and other institutions has built such a map, creating a massive catalog of the body's proteins as they relate to the stages of diabetes. Proteins are the tiny machines and messengers that carry out almost every task in the human body, and their levels in the blood change when something is wrong. The researchers analyzed blood samples from nearly 42,000 people in the UK Biobank, measuring more than 2,900 different proteins. They sorted these people into three groups based on their blood sugar levels: those with normal sugar, those with pre-diabetes, and those who developed type 2 diabetes during the study. By comparing the protein levels across these groups, they created a detailed atlas called the Metabolic Atlas of the Proteome in Diabetes, or MAP-D. This atlas reveals that the body does not react to fat, insulin resistance, and high blood sugar in the same way. Instead, these three factors drive distinct chemical changes. For instance, the study found that body fat acts like a broad sculptor, reshaping the levels of many proteins across the board. In contrast, high blood sugar appears to be driven by specific proteins that act as upstream causes, rather than just being a passive result of the sugar levels themselves.
To see if these biological patterns could be fixed, the researchers compared their atlas against data from major clinical trials involving semaglutide, a popular medication known as a GLP-1 receptor agonist that helps lower blood sugar and weight. They looked at whether the drugs could reverse the protein changes they had identified in the atlas. The results were revealing. While the medication successfully reversed many of the protein shifts associated with weight and insulin resistance, a significant number of proteins remained stubbornly out of balance even after treatment. These "persistent" proteins did not return to normal levels, suggesting that the drug, while effective for many symptoms, leaves behind a specific biological signature that is not fully addressed by the treatment alone. The researchers then tested whether these stubborn proteins were linked to future health risks. They found that people with higher levels of these persistent proteins were more likely to develop coronary artery disease, a serious condition where the heart's blood vessels become narrowed or blocked. This suggests that even when a patient's weight and blood sugar improve, these lingering protein imbalances might continue to put their heart at risk.
The study also used a clever genetic technique to figure out the direction of cause and effect. By looking at how genetic variations influence protein levels and disease traits, the team could tell whether a protein was causing a change in the body or simply reacting to it. They discovered that for body mass index, the fat tissue itself seems to drive the changes in protein levels. However, for blood sugar, the relationship is different: certain proteins appear to drive the changes in sugar levels, rather than just reacting to them. This distinction is crucial because it suggests that targeting these specific proteins could be a way to control blood sugar more effectively. Furthermore, the researchers found that some of these persistent, heart-risk proteins are already targets for existing medications. This opens the possibility that doctors might one day combine current diabetes treatments with other drugs to target these stubborn proteins, potentially offering better protection against heart disease for patients who do not fully respond to standard therapy.
The researchers did not stop at identifying the problem; they also looked at which specific proteins were most responsible for the remaining risk. They found that proteins involved in inflammation and cellular stress were among those that remained high despite treatment. These are not just markers of the disease but active participants in the damage to blood vessels. The study highlights that while modern drugs are powerful, they may not reset the entire biological system to a healthy state. Some pathways, particularly those related to inflammation and stress, seem to persist. By identifying these specific proteins, the study provides a list of new targets for future research and drug development. It suggests that the next generation of diabetes care might involve looking beyond just blood sugar and weight, focusing instead on clearing out these residual biological risks to prevent heart disease. The work serves as a reminder that the body is a complex network, and fixing one part of the system does not always fix the whole, but by mapping the connections, scientists can find new ways to heal the rest.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.